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Cancer Prevention by Different Forms of Tocopherols
CHUNG S. YANG*, GUANGXUN LI AND ZHIHONG YANG
Department of Chemical Biology, Center for Cancer Prevention Research, Ernest Mario School of Pharmacy,
Rutgers, The State University of New Jersey, U.S.A.

ABSTRACT
Low vitamin E nutritional status has been suggested to increase cancer risk. However, recent large-scale human trials with
high doses of alpha-tocopherol (-T) have produced disappointing results. This points out the need for a better understanding of
the biological activities of different forms of tocopherols. Using a tocopherol mixture that is rich in -T (-TmT), we
demonstrated the inhibition of colon carcinogenesis in mice, and the inhibition is associated with decreased levels of
8-isoprostane, nitrotyrosine, prostaglandin E2 and leukotriene B4. Dietary 0.3% -TmT also inhibited chemically induced lung
tumorigenesis in the A/J mice as well as the growth of lung cancer cells in xenograft or allograft tumors; the inhibition was
associated with a reduction of oxidative/nitrosative stress. -T was found to be more active than -T in the inhibition of cancer
cell growth in culture and lung cancer xenograft tumors as well as in azoxymethane-induced colon aberrant crypt foci formation
in rats, whereas -T was ineffective. Analysis of the levels of tocopherols and their metabolites in blood and tissues suggests that
metabolites of -T and -T contribute to their inhibitory activity. These studies demonstrate the broad cancer preventive activity
of -TmT and higher activity of -T.
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INTRODUCTION
Tocopherols, collectively known as vitamin E, are a
family of fat-soluble phenolic compounds.
Each
tocopherol contains a chromanol ring system and a phytyl
chain containing 16 carbons. Depending upon the
number and position of methyl groups on the chromanol
ring, they exist as -, β-, -, or -tocopherols (-, β-, -,
or -T)(1). The structures of these tocopherols are shown
in Figure 1. α-T is trimethylated at the 5-, 7- and
8-positions of the chromanol ring, whereas -T is
dimethylated at the 7- and 8-positions and -T is
methylated at the 8-position. The unmethylated carbons
at 5- and 7-positions are electrophilic centers, which
effectively trap reactive oxygen and nitrogen species
(RONS). The formation of 5-nitro--T, 5-nitro--T,
7-nitro--T, and 5,7-dinitro--T have been reported(2).
The hydrocarbon tail and ring structure provide the
lipophilicity for tocopherols to be incorporated into the
lipid bilayers of biological membranes. The phenolic
group in the chromanol moiety effectively quenches lipid
free radicals by one electron reduction. The resulting
tocopherol phenoxy radical, can be reduced by ascorbic
acid or glutathione to regenerate the tocopherol molecule.
This is probably the most important physiological
antioxidant mechanism to protect the integrity of
biological membranes. In this article, we will briefly
discuss the cancer preventive activities of different forms
of tocopherols based on results from human studies and
our recent results from studies in animal models.

Figure 1. Structures of tocopherols.

HUMAN STUDIES ON TOCOPHEROLS AND
CANCER
Because of the involvement of RONS in carcinogenesis, tocopherols, as effective antioxidants, are expected to protect against carcinogenesis. There is evidence to support this concept. For example, of the three
reported cohort studies on lung cancer, two studies found
a significant inverse association between dietary intake of
vitamin E and risk of lung cancer(3). In both of these
studies, the protective effects were found in current
smokers, suggesting a protective effect of vitamin E
against insult from cigarette smoking. In four case-control
studies on lung cancer, three studies found lower serum
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-T levels in lung cancer patients than in matched controls(3). In a recent case-control study, Mahabir et al.(4)
observed that the odds ratios of lung cancer for increasing
quartiles of dietary -T intake were 1.0, 0.63, 0.58, and
0.39, respectively (p for trend < 0.0001)(4). The authors
concluded that -T accounts for 34 - 53% reduction in
lung cancer risk. Since the intake of -T was also increased in proportion to -T, and at higher quantities, the
beneficial effect could also be due to -T or the combined
effects of all the forms of tocopherols. -T is 3 to 4 times
more abundant than -T and -T could also be more abundant than -T in our diet. -T and -T have also been
shown to be more effective in trapping reactive nitrogen
species(2).
Because -T is the most abundant form of tocopherols in blood and tissues and has the highest activity in
the classical fertility-restoration assay, -T is generally
considered to be “the vitamin E”(1). Therefore, many
studies on vitamin E have been conducted with
-tocopheryl acetate. The results from several large-scale
intervention studies with -T, however, have been disappointing(5-8). For example, in the recent Selenium and
Vitamin E Cancer Prevention Trial (SELECT), taking 400
IU all-rac α-tocopheryl acetate or 200 g selenium from
L-selenomethionine, or both, daily for an average of 5
years, did not prevent prostate or other cancer(7). In the
recently published results on the follow-up (for 7-12
years) of this study, subjects receiving -tocopherol acetate had a hazard ratio of 1.17 for developing prostate
cancer(8). It was noted that the α-T supplement caused a
50% decrease in median plasma -T levels(7). A possible
interpretations of the result is that supplementation of a
nutrient to a population that is already adequate in this
nutrient may not produce any beneficial effects. It is also
possible that supplementation of a large quantity of -T
decreases the blood and tissue levels of -T, which has
been suggested to have stronger anti-inflammatory and
cancer preventive activities(3,9-13). The exact reasons for
these negative results are not known. Nevertheless, the
disappointing outcome of these large-scale trials reflects
our lack of understanding of the biological activities of
tocopherols and points to the need for systematic studies
of the disease preventive activities of the different forms
of tocopherols.

INHIBITION OF TUMORIGENESIS BY -TMT
IN ANIMAL MODELS
Previous cancer prevention studies in different animal models with pure -T have obtained inconsistent
results(3). On the other hand, recent studies from our research team at Rutgers University have demonstrated the
inhibition of cancer formation and growth in the lung,
colon, mammary gland, and prostate by a tocopherol
mixture that is rich in -T (-TmT)(14-21). -TmT is a
by-product in the distillation of vegetable oil and usually
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contains (per g) 130 mg -T, 15 mg -T, 568 mg -T, and
243 mg -T. Some studies on lung and colon cancer are
discussed in detail in the following sections.
I. -TmT Inhibits Lung Carcinogenesis
In studying the lung cancer preventive activity of
-TmT, we treated A/J mice (6 weeks old) with a tobacco
carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone (NNK), plus benzo[a]pyrene (B[a]P), a ubiquitous
environmental pollutant, at doses of 2 mol each, by oral
gavage weekly from Weeks 1 to 8. At Week 19, the mice
in the control group (on AIN93M diet) developed 21 tumors per mouse(14). Treatment of the mice with 0.3%
-TmT in the diet during the entire experimental period
lowered the tumor multiplicity to 14.8 (30% inhibition, p
< 0.05). -TmT treatment also significantly reduced the
average tumor volume and tumor burden by 50% and
55%, respectively(14).
In a second study, lung tumorigenesis was induced
by NNK (i.p. injection of 100 mg/kg on Week 1 and 75
mg/kg on Week 2). The 0.3% -TmT diet was given during the carcinogen-treatment stage, the post-initiation
stage, or the entire experimental period. -TmT treatment
during these three time periods all reduced the tumor
multiplicity (17.1, 16.7 and 14.7 per mouse, respectively,
as compared to 20.8 in the control group; p < 0.05).
Moreover, the tumor burden was significantly reduced by
-TmT treatment given during the tumor initiation stage
or during the entire experimental period by 36% and 43%
inhibition, respectively(14).
In the NNK plus B[a]P-treated model, dietary -TmT
treatment significantly increased the apoptotic index
(based on cleaved-caspase-3 positive cells) from 0.09 to
0.25% in the lung tumors; whereas the treatment did not
affect apoptosis in non-tumorous lung tissues. Dietary
-TmT treatment also significantly decreased the percentage of cells with positive immunostaining for
8-hydroxydeoxyguanosine (8-oxo-dG) (from 26 to 17%),
a marker for oxidative DNA damage, as well as for
-H2AX (from 0.51 to 0.23%), a reflection of double-strand break-induced DNA repair. The plasma levels of prostaglandin E2 (PGE2) and leukotriene B4 (LTB4)
were markedly elevated in the tumor-bearing A/J mice at
Week 19 as compared to mice that received no carcinogen
treatment. -TmT treatment resulted in lower plasma levels of PGE2 (by 61%, p < 0.05) and LTB4 (by 12.7%, p <
0.1). These results suggest the antioxidant and
anti-inflammatory activities of -TmT.
The
anti-angiogenic activity of dietary -TmT was demonstrated with anti-endothelial cell CD31 antibodies.
CD31-labeled capillary clusters and blood vessels were
observed mainly in the peripheral area of the lung adenomas, and dietary -TmT reduced the microvessel density (blood vessels/mm2) from 375 to 208 (p < 0.05)(14).
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II. - and -Tocopherols and -TmT Inhibit Xenograft
Lung Tumorigenesis and Tumor Growth
When 0.3% -TmT was given to NCr nu/nu mice in
the diet one day after implantation of human lung H1299
cells (1 × 106 cells injected s.c. per site to both flanks of
the mouse), an inhibition of xenograft tumor growth was
observed(14). After 6 weeks, the tumor size and weight
were significantly reduced by 56 and 47%, respectively,
as compared to the control group. The -TmT treatment
also caused a 3.3-fold increase in apoptotic index as well
as a 52% decrease in 8-oxo-dG-positive cells and a 57%
decrease in -H2AX-positive cells in the xenograft tumors. Strong cytoplasmic staining of nitrotyrosine was
observed in xenograft tumors, and the staining intensity
was decreased by 44% in mice that received -TmT.
The -TmT treatment also reduced the plasma LTB4 level
by 36.5% (p < 0.05)(14).
In a similar experiment, the effectiveness of different
forms of pure tocopherols in the inhibition of H1299
xenograft tumor growth was compared(15). Pure -T was
most effective, showing dose-response inhibition when
given at 0.17 and 0.3% in the basal AIN-93M diet.
-TmT and pure -T were less effective, but -T was not
effective at diet levels of 0.17 and 0.3%. Studies of
H1299 cells in culture also showed that -T was more
effective than -TmT and -T in inhibiting cell growth,
whereas -T was not effective(14).
In another transplanted tumor study, dietary 0.1 and
0.3% -TmT were found to inhibit the growth of subcutaneous tumors (formed by injection of murine lung cancer CL13 cells) in A/J mice by 54 and 80%, respectively,
on Day 50(16).
III. Tocopherols
Tumorigenesis

Inhibit

Colon

Inflammation

CONCLUDING REMARKS
In collaboration with Dr. Nanjoo Suh, we demonstrated
the
dose-dependent
inhibition
of
N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 0.1, 0.3, and 0.5% of γ-TmT in the diet, and
the inhibition was associated with the activation of
PPAR-γ and the downregulation of estrogen signaling(18,
19)
. In collaboration with Dr. Xi Zheng, we also showed
the inhibition of LNCaP prostate cancer growth in a xenograft tumor model(20). The inhibition of prostate carcinogenesis in TRAMP mice by -TmT was reported by
Barve et al.(21). In the transgenic rat for adenocarcinoma
of prostate (TRAP) model, -T, but not -T, inhibited
adenocarcinoma formation in the ventral lobe(22).
Overall, -TmT has been demonstrated to have broad
cancer preventive activity. We have also shown that -T
and -T are effective cancer preventive agents, whereas
-T is not. A common mechanism of action appears to be
the trapping of RONS. In addition to trapping RONS, and -T can be efficiently converted to side-chain
metabolites, which retain the intact chromanol ring and
may possess cancer preventive activities. Other
mechanisms remain to be studied. When a high dose of
-T is used, it may decrease the blood and tissue levels of
-T and diminish its cancer preventive activity(7,8).
Practical use of tocopherols for cancer prevention needs
to be further studied.

and

Previous studies concerning the effect of α-T on
colon carcinogenesis have yielded mostly negative
results(3). Recently, we studied the effect of -TmT in the
colons of mice that had been treated with azoxymethane
(AOM) and dextran sulfate sodium (DSS)(17). Dietary
-TmT treatment (0.3% in the diet) resulted in a
significantly lower colon inflammation index (52% of the
control) on Day 7, and reduced the number of colon
adenomas (to 9% of the control) on Week 7. -TmT
treatment also resulted in higher apoptotic indexes in
adenomas, lower PGE2, LTB4, and nitrotyrosine levels in
the colon, and lower PGE2, LTB4, and 8-isoprostane
levels in the plasma on Week 7. In a second experiment,
with AOM/DSS-treated mice sacrificed on Week 21,
dietary -TmT treatment significantly inhibited
adenocarcinoma and adenoma formation in the colon (to
17 - 33% of the control). In a third experiment, mice
received dietary treatment with 0, 0.1, and 0.3% -TmT in
the AIN 93M basal diet. One week later, 1% DSS was
given to mice in drinking water for one week to induce
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inflammation, and a dose-dependent anti-inflammation
was also observed(17). These studies demonstrate the
anti-inflammatory and anti-carcinogenic activities of
-TmT in the colon.
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